— Tandem Diabetes (NASDAQ: TNDM) reported earnings of $0.04 per share in the fourth quarter of 2019, vs $0.05 per share loss expected
— Q4 Sales grew 42% to $108.4 million, vs. $109.2 million expected
— Worldwide pump shipments increased 21% to 19,602 pumps in Q4
— For FY20, sales are estimated to be in the range of $450 million to $465 million, up 24% to 28%. Adjusted EBITDA is estimated to be 12% to 14%
— TNDM fell 3.8% immediately following the announcement.